Scientific Opinion on the substantiation of health claims related to konjac mannan (glucomannan) and reduction of body weight (ID 854, 1556, 3725), reduction of post-prandial glycaemic responses (ID 1559), maintenance of normal blood glucose concentrations (ID 835, 3724), maintenance of normal (fasting) blood concentrations of triglycerides (ID 3217), maintenance of normal blood cholesterol concentrations (ID 3100, 3217), maintenance of normal bowel function (ID 834, 1557, 3901) and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 1558) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition andAllergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 ofRegulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claimsin relation to konjac mannan (glucomannan) and reduction of body weight, reduction of post-prandialglycaemic responses, maintenance of normal blood glucose concentrations, maintenance of normal(fasting) blood concentrations of triglycerides, maintenance of normal blood cholesterolconcentrations, maintenance of normal bowel function and decreasing potentially pathogenic gastro-intestinal microorganisms. The scientific substantiation is based on the information provided by theMember States in the consolidated list of Article 13 health claims and references that EFSA hasreceived from Member States or directly from stakeholders.The food constituent that is the subject of the health claims is konjac mannan (glucomannan). ThePanel considers that konjac mannan (glucomannan) is sufficiently characterised.